In this series, we’re exploring how we use our defining edge to bring clarity and credibility to policy debates. As the debate on “Most Favored Nation” policies started to heat up last year, No Patient Left Behind delivered issue briefs and comment letters that helped media and regulators better understand this policy’s risks. We also used analyses to share our concerns about the Inflation Reduction Act’s pill penalty.

In this series, we’re exploring how we use our defining edge to bring clarity and credibility to policy debates. When FDA capabilities and NIH funding first came under threat last year, No Patient Left Behind activated our network to gather real-time, actionable insights.

If we systematically undervalue medicine, we’ll under-invest in future innovation, which means we’ll end up with fewer of the breakthroughs we desperately need. That leaves us all worse off. Let's stop overlooking elements of value. The transplant that changed my life is proof that investing in innovation pays dividends for patients, for caregivers, for the health care system, and for all of us.

For people living with chronic disease, health insurance shouldn’t be another hurdle. We should spend our energy and focus fighting for the best lives we can, not fighting against insurance companies. To learn more about how to #FixInsurance so it works as it should, visit https://www.nopatientleftbehind.org/fixinsurance.

My kidneys started failing when I was just five years old. Decades later, ongoing innovation has kept me alive. This National Kidney Month, let’s celebrate progress and push for policies that ensure treatment advances are affordable and accessible. Learn more at https://www.nopatientleftbehind.org/protect-innovation.

In her first message as Executive Director, Priscilla VanderVeer discusses No Patient Left Behind’s commitment to patient access, innovation, and policy credibility.

Our modern world needs a modern Food and Drug Administration (FDA). As PDUFA VIII offers a historic opportunity to make the drug review program faster, more consistent, and more transparent, here are a few suggestions we heard from our network of experts.

“You shouldn’t have to fight your cancer and your insurance company’s co-payments."

Cambridge is home to the world's most innovative biotech companies. Resident Neil Kairen explains the importance of this industry and suggests explanations for why so many misunderstand its value.

Here are five policies President Biden should include in his State of the Union address on Thursday.

Researchers in Pennsylvania are working on a cure for Parkinson’s. Price controls threaten their progress.

A company in Virginia is working on a vaccine to protect babies from rotavirus and norovirus.

NPLB noted that including factors, such as diminishing returns and dynamic pricing, helps assess medication value better than traditional CEA.

Rubin speaks about how drugs aren’t being properly valued.